304 related articles for article (PubMed ID: 29194014)
1. Respiratory syncytial virus seasonality and its implications on prevention strategies.
Janet S; Broad J; Snape MD
Hum Vaccin Immunother; 2018 Jan; 14(1):234-244. PubMed ID: 29194014
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis.
Guo L; Deng S; Sun S; Wang X; Li Y
Lancet Glob Health; 2024 Jun; 12(6):e1005-e1016. PubMed ID: 38670132
[TBL] [Abstract][Full Text] [Related]
4. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
Campbell PT; Geard N; Hogan AB
BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
7. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy.
Mapindra MP; Mahindra MP; McNamara P; Semple MG; Clark H; Madsen J
Neonatology; 2024; 121(3):271-282. PubMed ID: 38286126
[TBL] [Abstract][Full Text] [Related]
9. Advances in and the potential of vaccines for respiratory syncytial virus.
Jorquera PA; Oakley KE; Tripp RA
Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
[TBL] [Abstract][Full Text] [Related]
10. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
Rainisch G; Adhikari B; Meltzer MI; Langley G
Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
[TBL] [Abstract][Full Text] [Related]
12. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
13. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?
Saso A; Kampmann B
Lancet Infect Dis; 2016 Aug; 16(8):e153-63. PubMed ID: 27317449
[TBL] [Abstract][Full Text] [Related]
14. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
15. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus vaccine: where are we now and what comes next?
Noor A; Krilov LR
Expert Opin Biol Ther; 2018 Dec; 18(12):1247-1256. PubMed ID: 30426788
[TBL] [Abstract][Full Text] [Related]
17. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
[TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
[TBL] [Abstract][Full Text] [Related]
19. The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015.
Hardelid P; Verfuerden M; McMenamin J; Smyth RL; Gilbert R
Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621817
[TBL] [Abstract][Full Text] [Related]
20. Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.
Abu-Raya B; Reicherz F; Lavoie PM
Clin Rev Allergy Immunol; 2022 Dec; 63(3):371-380. PubMed ID: 35689745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
